Results 181 to 190 of about 18,081 (213)

Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease. [PDF]

Pathophysiology
Hettenbach A, Elger T, Huss M, Liebisch G, Höring M, Loibl J, Kandulski A, Müller M, Tews HC, Buechler C.   +9 more
europepmc   +1 more source

Anti-inflammatory effects of proprotein convertase subtilisin/kexin 9 inhibitor therapy in the early phase of acute myocardial infarction. [PDF]

Heart Vessels
Shimizu T, Morishita T, Uzui H, Sato Y, Kataoka T, Miyoshi M, Yamaguchi J, Shiomi Y, Ikeda H, Tama N, Hasegawa K, Ishida K, Tada H.   +12 more
europepmc   +1 more source

Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia. [PDF]

J Cachexia Sarcopenia Muscle
Jiang H, Li L, Zhang X, He J, Chen C, Sun R, Chen Y, Xia L, Wen L, Chen Y, Liu J, Zhang L, Lv W.   +12 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Improves the Vascular Function of Arteriovenous Fistula in Rats with Hyperglycemia. [PDF]

Acta Cardiol Sin
Wang YC, Ho HY, Kuo LP, Fang SY, Chiu MH, Liu ZY, Lam CF, Huang YC, Roan JN.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Proprotein convertases: lessons from knockouts

The FASEB Journal, 2006
The physiological role of the subtilisin/kexin‐like proprotein convertases (PCs) in rodents has been examined through the use of knockout mice. This review will summarize the major in vivo defects that result from the disruption of the expression of their genes.
Nathalie, Scamuffa, Fabien, Calvo, Michel, Chrétien, Nabil G, Seidah, Abdel-Majid, Khatib   +4 more
openaire   +2 more sources

Proprotein convertases as therapeutic targets

Expert Opinion on Therapeutic Targets, 2008
Limited endoproteolysis of precursor proteins is a common mechanism of production of functional proteins and peptides. In the secretory pathway of eukaryotic cells, this endoproteolysis is principally mediated by a family of calcium-dependent serine proteases, generically known as proprotein convertases.
Michel, Chrétien, Nabil G, Seidah, Ajoy, Basak, Majambu, Mbikay   +3 more
openaire   +2 more sources

The proprotein convertases

Current Opinion in Chemical Biology, 1998
The major endoproteolytic processing enzymes of the secretory pathway are the subtilisin-like proprotein convertases (SPCs). Furin (SPC1) has emerged as one of the major processing enzymes of the constitutive secretory pathway and its localization in the trans-Golgi network and mechanism of autoactivation have been studied in considerable detail ...
openaire   +2 more sources

Inhibitors of proprotein convertases

Journal of Molecular Medicine, 2005
The discovery of mammalian subtilases, proprotein convertases (PCs) or subtilisin-like proprotein convertases (SPCs), in 1990 was a result of sustained efforts in searching for enzyme/s responsible for maturation of inactive protein precursors. Since then, seven PCs have so far been discovered that cleave at the carboxy-terminal of a basic amino acid ...
openaire   +2 more sources

Proprotein convertases in atherogenesis

Current Opinion in Lipidology, 2015
The proprotein convertases subtilisin/kexin (PCSKs) are endoproteases identified as activators of precursors from hormones and peptides. On the basis of the variety of substrates and regulation in disease, they have been recognized as mediators in atherogenesis.
openaire   +2 more sources